1. Search Result
Search Result
Results for "

cAMP-signaling

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117958
    HJC0197
    1 Publications Verification

    Ras Cardiovascular Disease Metabolic Disease Cancer
    HJC0197 is a potent Epac1 (exchange protein directly activated by cAMP 1) and Epac2 (IC50=5.9 μM for Epac2) antagonist. HJC0197 selectively blocks cAMP-induced Epac activation. HJC0197 inhibits Epac1-mediated Rap1-GDP exchange activity at 25 μM in the presence of equal concentration of cAMP .
    HJC0197
  • HY-108742
    Abaloparatide
    1 Publications Verification

    BA 058; BIM 44058

    PTHR Arrestin Metabolic Disease Cancer
    Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .
    Abaloparatide
  • HY-108742A
    Abaloparatide TFA
    1 Publications Verification

    BA 058 TFA; BIM 44058 TFA

    Arrestin PTHR Metabolic Disease Endocrinology Cancer
    Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .
    Abaloparatide TFA
  • HY-122197

    CXCR Apelin Receptor (APJ) Arrestin Cancer
    ML339 is a selective CXCR6 antagonist with an IC50 of 140 nM. ML339 antagonizes β-arrestin recruitment and cAMP signaling pathway of human CXCR6 receptor induced by CXCL16, with IC50 of 0.3 μM and 1.4 μM, respectively. ML339 shows weaker activity against the recruitment of β-arrestin in mouse CXCR6 receptors, with an IC50 of 18 μM. ML339 has no inhibitory effect on CXCR5CXCR4CXCR6 and apelin receptor (APJ), with IC50 >79 μM. ML339 has the potential to promote the development of prostate cancer research .
    ML339
  • HY-108991

    (-)-T-0509

    Adrenergic Receptor Cardiovascular Disease
    T-0509 ((-)-T-0509) is a selective full agonist of the β1 receptor. T-0509 activates the cAMP signaling pathway through the β1 receptor and enhances myocardial contractility .
    T-0509
  • HY-153542

    Others Others
    AP-C6 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.5. AP-C6 concentration-dependently inhibits human cGKII activity in vitro. AP-C6 potentiate cAMP signaling by PDE inhibition .
    AP-C6
  • HY-162401

    RXFP Receptor Cardiovascular Disease
    AZ7976 (Compound 42) is a highly selective agonist for the Relaxin Family Peptide Receptor 1 (RXFP1) (pEC50 > 10.5). AZ7976 enhances RXFP1's cAMP signaling through an allosteric mechanism, thereby physiologically increasing heart rate. AZ7976 can be used in the field of cardiovascular disease research .
    AZ7976
  • HY-137381

    N6-Benzoyl-cAMP

    Potassium Channel Others
    6-Bnz-cAMP (N6-Benzoyl-cAMP), a derivative of cyclic adenosine monophosphate (cAMP), is a potent inhibitor of the bTREK-1 potassium channel. 6-Bnz-cAMP can strongly inhibit the bTREK-1 potassium channel through a protein kinase A (PKA) independent mechanism. 6-Bnz-cAMP can be used to explore potential signal transduction proteins in the cAMP signaling pathway .
    6-Bnz-cAMP

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: